subcutaneous injections

Summary

Summary: Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.

Top Publications

  1. ncbi Pain perception after subcutaneous injections of media containing different buffers
    Torben Laursen
    Medical Department M Diabetes and Endocrinology, Aarhus Sygehus, NBG, Aarhus University Hospital, Aarhus, Denmark
    Basic Clin Pharmacol Toxicol 98:218-21. 2006
  2. pmc Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    E C Keystone
    University of Toronto and Mount Sinai Hospital, Ontario, Canada
    Ann Rheum Dis 68:789-96. 2009
  3. ncbi Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home
    Uwe Nicolay
    Section of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    J Clin Immunol 26:65-72. 2006
  4. ncbi Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    R M Neer
    Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:1434-41. 2001
  5. ncbi Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
    Arne Astrup
    Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark
    Lancet 374:1606-16. 2009
  6. ncbi Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males
    Birgitte Sloth
    Dept of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, Univ of Copenhagen, 30 Rolighedsvej, DK 1958 Frederiksberg, Denmark
    Am J Physiol Endocrinol Metab 293:E604-9. 2007
  7. ncbi Crossover trial of analgesic efficacy of glucose and pacifier in very preterm neonates during subcutaneous injections
    Ricardo Carbajal
    Poissy Neonatal Intensive Care Unit, Poissy Saint Germain Hospital, Poissy, France
    Pediatrics 110:389-93. 2002
  8. ncbi Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults
    T Laursen
    Center for Clinical Pharmacology, Department of Pharmacology, Aarhus University, Denmark
    J Clin Endocrinol Metab 86:1222-8. 2001
  9. ncbi Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function
    Carolina Griselda Luchetti
    Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacologicos y Botanicos CEFYBO, Consejo Nacional de Investigaciones Cientificas y Tecnicas CONICET, Serrano 669, C1414DEM Buenos Aires, Argentina
    J Reprod Immunol 64:59-74. 2004
  10. ncbi Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique
    Shigeyuki Takada
    Drug Formulation Research Laboratories, Takeda Chemical Industries, Ltd, 2 17 85, Juso honmachi, Yodogawa ku, Osaka 532 8686, Japan
    J Control Release 88:229-42. 2003

Detail Information

Publications224 found, 100 shown here

  1. ncbi Pain perception after subcutaneous injections of media containing different buffers
    Torben Laursen
    Medical Department M Diabetes and Endocrinology, Aarhus Sygehus, NBG, Aarhus University Hospital, Aarhus, Denmark
    Basic Clin Pharmacol Toxicol 98:218-21. 2006
    Several hormones are administered by daily subcutaneous injections. Pain caused by subcutaneous injection is an unpleasant condition, which can limit patient compliance...
  2. pmc Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    E C Keystone
    University of Toronto and Mount Sinai Hospital, Ontario, Canada
    Ann Rheum Dis 68:789-96. 2009
    ..The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy...
  3. ncbi Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home
    Uwe Nicolay
    Section of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    J Clin Immunol 26:65-72. 2006
    ..Treatment satisfaction was significantly improved in Group A. The preference for the subcutaneous route and for home therapy was respectively 81% and 90% in Group A. In Group B, 69% preferred the subcutaneous route and 92% home therapy...
  4. ncbi Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    R M Neer
    Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:1434-41. 2001
    ..The 40-microg dose increased bone mineral density more than the 20-microg dose but had similar effects on the risk of fracture and was more likely to have side effects...
  5. ncbi Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
    Arne Astrup
    Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark
    Lancet 374:1606-16. 2009
    ..We assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes...
  6. ncbi Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males
    Birgitte Sloth
    Dept of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, Univ of Copenhagen, 30 Rolighedsvej, DK 1958 Frederiksberg, Denmark
    Am J Physiol Endocrinol Metab 293:E604-9. 2007
    ..PYY(1-36) is unlikely to be important in regulating energy intake. The PYY(3-36) administrations caused a non-dose-dependent mobilization of FFA, likely through a direct effect...
  7. ncbi Crossover trial of analgesic efficacy of glucose and pacifier in very preterm neonates during subcutaneous injections
    Ricardo Carbajal
    Poissy Neonatal Intensive Care Unit, Poissy Saint Germain Hospital, Poissy, France
    Pediatrics 110:389-93. 2002
    ..the analgesic effect of orally administered glucose and to determine the synergetic analgesic effect of glucose and pacifiers during subcutaneous injections in very preterm neonates using a validated behavioral acute pain rating scale.
  8. ncbi Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults
    T Laursen
    Center for Clinical Pharmacology, Department of Pharmacology, Aarhus University, Denmark
    J Clin Endocrinol Metab 86:1222-8. 2001
    ..The data on insulin sensitivity and lipoproteins suggest that constant GH exposure is as safe as intermittent GH administration...
  9. ncbi Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function
    Carolina Griselda Luchetti
    Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacologicos y Botanicos CEFYBO, Consejo Nacional de Investigaciones Cientificas y Tecnicas CONICET, Serrano 669, C1414DEM Buenos Aires, Argentina
    J Reprod Immunol 64:59-74. 2004
    ..These results show that the development of cysts involves changes in ovarian function and an imbalance in the oxidant-antioxidant equilibrium. We observed also both an increased and selective T lymphocyte infiltration...
  10. ncbi Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique
    Shigeyuki Takada
    Drug Formulation Research Laboratories, Takeda Chemical Industries, Ltd, 2 17 85, Juso honmachi, Yodogawa ku, Osaka 532 8686, Japan
    J Control Release 88:229-42. 2003
    ....
  11. pmc Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
    G H Windbichler
    Department of Obstetrics and Gynaecology, University Hospital, Innsbruck, Austria
    Br J Cancer 82:1138-44. 2000
    ..Thus, with acceptable toxicity, the inclusion of IFN-gamm in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival...
  12. ncbi Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
    K Wynne
    Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital, London, UK
    Int J Obes (Lond) 30:1729-36. 2006
    ..Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy...
  13. ncbi Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
    K A Bauer
    Department of Medicine, Veterans Affairs Boston Healthcare System and Beth Israel Deaconess Medical Center, MA 02215, USA
    N Engl J Med 345:1305-10. 2001
    ..Despite thromboprophylaxis, major knee surgery carries a high risk of venous thromboembolism. Fondaparinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk...
  14. ncbi Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study
    Bengt I Eriksson
    Orthopedics Department, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Arch Intern Med 163:1337-42. 2003
    ..The benefit of thromboprophylaxis for 1 month has never been evaluated in patients undergoing hip fracture surgery, a setting in the highest risk category for postoperative venous thromboembolism (VTE)...
  15. pmc Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective
    J S Bevan
    Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
    Clin Endocrinol (Oxf) 68:343-9. 2008
    ..The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety...
  16. ncbi Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells
    Woei Cherng Shyu
    Department of Neurology, Neuro Medical Scientific Center, Tzu Chi Buddhist General Hospital, Tzu Chi University, Hualien, Taiwan
    Circulation 110:1847-54. 2004
    ..Stroke is a leading cause of death and disability worldwide; however, no effective treatment currently exists...
  17. ncbi Calcinosis cutis: a rare reaction to subcutaneous injections of calcium-containing heparin in patients with renal failure
    Olivia Boccara
    Department of Pathology, Necker Enfants Malades Hospital, APHP, Rene Descartes University, Paris, France
    Am J Dermatopathol 32:52-5. 2010
    ..A retrospective inquiry confirmed that subcutaneous injections of calcium-containing heparin had been performed on the sites where lesions occurred...
  18. ncbi Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema
    Marco Cicardi
    Universita degli Studi di Milano, Milan
    N Engl J Med 363:532-41. 2010
    ..Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist...
  19. ncbi [Analgesic effects of Emla cream and saccharose solution for subcutaneous injections in preterm newborns: a prospective study of 265 injections]
    V Mucignat
    Service de Neonatologie, Hopital Armand Trousseau, AP HP, 26, avenue du Dr Arnold Netter, 77571 Paris Cedex 12, France
    Arch Pediatr 11:921-5. 2004
    ..To compare the analgesic effects of non nutritive pacifier sucking, oral administration of a 30% saccharose solution, local application of Emla and their association for subcutaneous injection of erythropoietin (EPO) in preterm infants...
  20. ncbi A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide
    Phillip Kelly
    Department of Endocrinology, St Bartholomew s Hospital, West Smithfield, London, EC1A 7BE, United Kingdom
    Endocr Pract 16:191-7. 2010
    ..To evaluate the efficacy of lanreotide Autogel, a depot preparation of a long-acting somatostatin analogue, in patients with acromegaly who were previously treated with octreotide...
  21. ncbi Bullous hemorrhagic dermatosis occurring at sites distant from subcutaneous injections of heparin: three cases
    Adeline Perrinaud
    Department of Dermatology, Universite Francois Rabelais, University Hospital of Tours, Tours, France
    J Am Acad Dermatol 54:S5-7. 2006
    ..We report 3 cases of intraepidermal hemorrhagic blisters occurring distant from sites of subcutaneous injections of heparin...
  22. ncbi Performing subcutaneous injections: a literature review
    Magdalena Annersten
    Oresund Diabetes Team AB, Lund, Sweden
    Worldviews Evid Based Nurs 2:122-30. 2005
    Persons using daily subcutaneous injections to administer medicine perform them in different ways and thereby increase the risk of skin complications related to the injection...
  23. ncbi Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
    Erik Naslund
    Division of Surgery, Karolinska Institutet Danderyd Hospital, SE 182 88 Danderyd, Sweden
    Br J Nutr 91:439-46. 2004
    ..In the present study, rGLP-1 was given for 5 d by prandial subcutaneous injections (PSI) (76 nmol 30 min before meals, four times daily; a total of 302...
  24. ncbi Acupuncture versus subcutaneous injections of sterile water as treatment for labour pain
    Lena Mårtensson
    School of Life Sciences, University of Skovde, Skovde, Sweden
    Acta Obstet Gynecol Scand 87:171-7. 2008
    ..Therefore, the aim of this study was to explore if there were any differences between acupuncture and sterile water injections regarding pain relief and relaxation during labour...
  25. ncbi Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:888-93. 2003
    ....
  26. ncbi A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
    A G Turpie
    McMaster University, Hamilton, Ont, Canada
    N Engl J Med 344:619-25. 2001
    ..To determine the optimal dose for phase 3 studies, we conducted a dose-ranging study in which Org31540/SR90107A was compared with a low-molecular-weight heparin, enoxaparin, in patients undergoing total hip replacement...
  27. ncbi A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
    Stefan Schreiber
    Hospital for General Internal Medicine, Christian Albrechts University, Klinik für Allgemeine Innere Medizin, Kiel, Germany
    Gastroenterology 129:807-18. 2005
    ..To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti-tumor necrosis factor, CDP870) in Crohn's disease...
  28. doi Continuous glucose monitoring and intensive treatment of type 1 diabetes
    William V Tamborlane
    N Engl J Med 359:1464-76. 2008
    ..The value of continuous glucose monitoring in the management of type 1 diabetes mellitus has not been determined...
  29. ncbi Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe
    Henrik Agersø
    Department of Clinical Pharmacology and Kinetics, Ferring Pharmaceuticals A S, Copenhagen, Denmark
    J Clin Pharmacol 42:1262-8. 2002
    ..5 hours. Comparison of the pharmacodynamic profiles (both IGF-1 and FFA) demonstrated bioequieffectiveness. These results support the use of jet injectors as a viable alternative to the traditional injection pens...
  30. pmc Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens
    N Okada
    Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina ku, Kyoto, 607 8414, Japan
    Br J Cancer 84:1564-70. 2001
    ..Furthermore, the immunization route affects vaccine efficiency...
  31. ncbi Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity
    Anke S Lonsdorf
    Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    J Immunol 171:3941-6. 2003
    ..The data show that intratumor injection of CpG-oligodeoxynucleotides is a promising strategy for rendering tumors immunogenic...
  32. ncbi TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunol 170:2004-13. 2003
    ..These insights could be used to monitor and potentially tune the immune response to cancer vaccines...
  33. ncbi A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma
    H Schmidt
    Department of Oncology, Aarhus University Hospital, Denmark
    Ann Oncol 13:1919-24. 2002
    ..Experimental data had suggested a synergistic effect of histamine with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha)...
  34. ncbi Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
    A Ravaud
    Department of Medicine, Institut Bergonie, Bordeaux, France
    J Clin Oncol 16:2728-32. 1998
    ..A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma...
  35. ncbi Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial
    Katie Wynne
    Department of Metabolic Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
    Diabetes 54:2390-5. 2005
    ..The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity...
  36. ncbi Subcutaneous injection of metallic mercury
    Y O Y Soo
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China
    Hum Exp Toxicol 22:345-8. 2003
    ..Therefore, early surgical removal of subcutaneous mercury deposits is required to prevent local complications and minimize the risk of systemic absorption and toxicity...
  37. ncbi Elemental mercury-induced subcutaneous granuloma. A case report and review of the literature
    Efstathios H Kayias
    2nd Orthopaedic Department, Naval Hospital of Athens, Greece
    Acta Orthop Belg 69:280-4. 2003
    ..On the contrary, there is a lack of reports of this soft-tissue injury in the orthopaedic literature...
  38. ncbi Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
    Benjamin M Segal
    Department of Neurology, Holtom Garrett Programme in Neuroimmunology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Lancet Neurol 7:796-804. 2008
    Repeated subcutaneous injections of a monoclonal antibody against the p40 subunit of interleukins 12 and 23, ustekinumab, were used to treat patients with relapsing-remitting multiple sclerosis (RRMS) to assess the drug's safety, ..
  39. ncbi Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats
    Megan J Shram
    Department of Neuroscience, Centre for Addiction and Mental Health, 33 Russell Street, T700, Toronto, ON, Canada M5S 2S1
    Psychopharmacology (Berl) 198:181-90. 2008
    ..Although adolescents may exhibit a greater susceptibility to nicotine addiction, relatively little is known about the influence of the aversive effects of nicotine withdrawal in maintaining smoking behavior...
  40. ncbi Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial
    Teresa Quattrin
    The Women and Children s Hospital of Buffalo, School of Medicine and Biochemical Sciences, State University of New York at Buffalo, Buffalo, New York 14222, USA
    Diabetes Care 27:2622-7. 2004
    ..The aim of this study was to determine whether premeal pulmonary delivery of rapid-acting, dry-powder insulin (Exubera) plus Ultralente could provide glycemic control comparable to a conventional insulin regimen in type 1 diabetes...
  41. ncbi Certolizumab pegol for the treatment of Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 357:228-38. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor alpha...
  42. ncbi Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment
    Ger Jan C M Sanderink
    Department of Drug Metabolism and Pharmacokinetics, Aventis Pharma, 13 quai Jules Guesde, BP 14, 94403 Vitry sur Seine, France
    Thromb Res 105:225-31. 2002
    ..Enoxaparin was administered once daily by subcutaneous injections at a dose of 40 mg for 4 days and venous blood samples were taken over a 5-day period to determine ..
  43. ncbi Metabolic responses of lactating dairy cows to single and multiple subcutaneous injections of glucagon
    G Bobe
    Nutritional Physiology Group, Department of Animal Science, Iowa State University, Ames 50011 3150, USA
    J Dairy Sci 86:2072-81. 2003
    ..The objective was to test whether single subcutaneous injections and multiple subcutaneous injections of glucagon delivered at 8-h intervals over 14 d improve the ..
  44. ncbi Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency
    B C J M Fauser
    Department of Reproductive Medicine and Gynecology, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Hum Reprod Update 15:309-21. 2009
    ..Co-expression of the alpha-subunit and the chimeric FSH beta-subunit produces a new recombinant molecule, named corifollitropin alfa, with a prolonged elimination half-life and enhanced in vivo bioactivity compared with wild-type FSH...
  45. ncbi Maximizing the value of validation findings to better understand treatment satisfaction issues for diabetes
    Meryl Brod
    The BROD GROUP, 219 Julia Avenue, Mill Valley, CA 94941, USA
    Qual Life Res 16:1053-63. 2007
    ..This study continues the validation process for the Insulin Treatment Satisfaction Questionnaire (ITSQ) while examining relationships between TS and these broader influences...
  46. pmc Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial
    Woei Cherng Shyu
    Neuro Medical Scientific Center, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan
    CMAJ 174:927-33. 2006
    ..We sought to examine the feasibility, safety and efficacy of using G-CSF to treat acute stroke...
  47. ncbi Subcutaneous injections as a risk factor of myositis ossificans traumatica in spinal cord injury
    Berrin Gunduz
    Physical Therapy and Rehabilitation Training Hospital, Ministry of Health, Istanbul, Turkey
    Int J Rehabil Res 30:87-90. 2007
    ..As a result, repeated injections under the spinal cord injury level should be avoided when possible because of the risk of myositis ossificans traumatica...
  48. ncbi Sumatriptan does not affect arteriovenous oxygen differences in jugular and cubital veins in normal human subjects
    T Wienecke
    Danish Headache Centre and Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark
    Cephalalgia 28:1081-5. 2008
    ..We also measured the AVDO2 in the internal jugular and cubital veins. There were no changes in AVDO2 after subcutaneous sumatriptan, probably because AVA blood flow is limited in humans with an intact sympathetic nervous system...
  49. ncbi Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg)
    Jean Claude Carel
    Groupe Hospitalier Cochin Saint Vincent De Paul, Faculté Cochin Université Paris V and Institut National de la Santé et de la Recherche Médicale U342, Paris 75014, France
    J Clin Endocrinol Metab 87:4111-6. 2002
    ..This regimen allows the reduction of the number of yearly injections from 12 to 4...
  50. ncbi Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
    John L Vahle
    Lilly Research Laboratories, Greenfield, Indiana 46140, USA
    Toxicol Pathol 30:312-21. 2002
    Fischer 344 rats (60/sex/group) were given daily subcutaneous injections of recombinant human parathyroid hormone (PTH)(1-34) for 2 years at doses of 0, 5, 30, or 75 microg/kg...
  51. ncbi Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  52. ncbi Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study
    Ann Gardulf
    Department of Laboratory Medicine, Section of Clinical Immunology, The Swedish Centre for Immunodeficiencies, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Clin Immunol 26:177-85. 2006
    ..In conclusion, the SCIG administration route was safe. High IgG levels were easily maintained resulting in a very good protection against infections...
  53. ncbi Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home
    Ann Gardulf
    Swedish Centre for Immunodeficiencies, Division of Clinical Immunology at the Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    J Allergy Clin Immunol 114:936-42. 2004
    ..It is mostly unknown what effect the choice of replacement therapy has on the patients' health-related quality of life (HRQOL) and treatment satisfaction (TS)...
  54. ncbi Subcutaneous immunoglobulin replacement in primary immunodeficiencies
    Melvin Berger
    School of Medicine, Case Western Reserve University, OH, USA
    Clin Immunol 112:1-7. 2004
    ..Obstacles may be encountered because no preparation of IgG is currently licensed for subcutaneous use in the US. Subcutaneous IgG replacement may be preferable to i.v. infusions or i.m. injections for carefully selected patients...
  55. ncbi Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin
    Anders Fasth
    Department of Paediatrics, University of Gothenburg, The Queen Silvia Children s Hospital, SE 416 85 Gothenburg, Sweden
    J Clin Immunol 28:370-8. 2008
    ..Among patients with antibody deficiency, patient-reported outcomes are important for choosing between equally effective treatment regimens...
  56. ncbi Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations
    Raffaello Bellosta
    Vascular surgery Unit Poliambulanza Foundation Hospital, Brescia
    Angiology 58:316-22. 2007
    ..In patients with active neoplasia, treatment with oral anticoagulant therapy must be considered...
  57. ncbi Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis
    C Pena-Rossi
    New Therapies, Merck Serono International S A, Geneva, Switzerland
    Aliment Pharmacol Ther 28:758-67. 2008
    ..Interferon (IFN)-beta-1a has potent immunoregulatory properties, including stimulation of host defence mechanisms and thus represents a potential treatment...
  58. ncbi Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days
    M Bronstein
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, Brazil
    Clin Endocrinol (Oxf) 63:514-9. 2005
    ..To investigate the pharmacokinetic profile of a prolonged release, aqueous Autogel formulation of the somatostatin analogue lanreotide (Lan-ATG)...
  59. ncbi Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium
    Antonio Ciccarelli
    Department of Endocrinology, University of Liege, Liege, Belgium
    Treat Endocrinol 3:77-81. 2004
    ..Patients receiving intramuscular lanreotide SR injections every 7-14 days can be switched to an appropriate dose of deep subcutaneous lanreotide Autogel every 28 days, without any impact on safety or loss of efficacy...
  60. ncbi Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus
    Alastair Carruthers
    Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
    Dermatol Surg 34:1486-99. 2008
    ..To evaluate the safety and effectiveness of soft tissue augmentation with calcium hydroxylapatite (CaHA) microspheres in an aqueous gel in patients with facial lipoatrophy (FLA) secondary to human immunodeficiency virus (HIV) disease...
  61. ncbi Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
    L Heinemann
    Department of Metabolic Diseases and Nutrition, the World Health Organization Collaborating Centre for Diabetes, Heinrich Heine University, Dusseldorf, Germany
    Diabetes Care 23:644-9. 2000
    ..To study the pharmacodynamic properties of the subcutaneously injected long-acting insulin analog HOE901 (30 microg/ml zinc) in comparison with those of NPH insulin and placebo...
  62. ncbi A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine
    Elizabeth A Doyle
    Department of Pediatrics and Children s Clinical Research Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Diabetes Care 27:1554-8. 2004
    ..Our principal aim in this short-term study was to compare the efficacy of CSII to MDI with glargine in lowering HbA(1c) levels in children and adolescents with type 1 diabetes...
  63. ncbi Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    J Drugs Dermatol 3:614-24. 2004
    ..The majority of patients experienced sustained efficacy with no increase in toxicity. This study is planned to continue; patients will receive up to 36 months of continuous efalizumab...
  64. ncbi Surgery for foreign body reactions due to injectable fillers
    Dolores Wolfram
    Department of Plastic and Reconstructive Surgery, Medical University of Innsbruck, Innsbruck, Austria
    Dermatology 213:300-4. 2006
    ..Depending on bioavailability, chemical composition and degradation, fillers can be classified as temporary or permanent, organic or inorganic and autologous or heterologous...
  65. ncbi Avoiding and treating dermal filler complications
    Gottfried Lemperle
    Division of Plastic Surgery, University of California, USA
    Plast Reconstr Surg 118:92S-107S. 2006
    ..Surgical excisions shall remain the last option and are indicated for hard lumps in the lips and visible hard nodules or hard granuloma in the subcutaneous fat...
  66. ncbi Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy
    John G Teeter
    Pfizer Global Research and Development, New London, CT 06320, USA
    Am J Respir Crit Care Med 173:1194-200. 2006
    ..Inhaled human insulin (INH; Exubera [human insulin (recombinant DNA origin) Inhalation Powder]) causes small changes in pulmonary function and increases in insulin antibodies compared with subcutaneous (SC) insulin...
  67. ncbi ArteFill: a long-lasting injectable wrinkle filler material--summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes
    Steven R Cohen
    Division of Plastic Surgery, Department of Dermatology, University of California, USA
    Plast Reconstr Surg 118:64S-76S. 2006
    ..Investigator Facial Fold Assessment ratings at 4 to 5 years were improved from baseline by 1.67 points (p < 0.001)...
  68. ncbi Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial
    Priscilla A Hollander
    Baylor University Medical Center, Endocrinology Center, 3600 Gaston Ave, Wadley Tower, Dallas, TX 75246, USA
    Diabetes Care 27:2356-62. 2004
    ....
  69. ncbi Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel)
    B Gutt
    Department of Internal Medicine Innenstadt, University of Munich, Germany
    Exp Clin Endocrinol Diabetes 113:139-44. 2005
    ..c. method of administration. Glucose metabolism has to be followed carefully in patients on high-dose Lanreotide Autogel...
  70. ncbi Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects
    Steven R Cohen
    Division of Plastic Surgery, University of California, San Diego, USA
    Plast Reconstr Surg 114:964-76; discussion 977-9. 2004
    ..Artecoll had fewer adverse events reported throughout the 12-month safety study period than the control group did in 6 months, although the difference was not statistically significant...
  71. ncbi Standardization of the single-breath diffusing capacity in a multicenter clinical trial
    Robert A Wise
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Chest 132:1191-7. 2007
    ..The safety assessment of inhalable insulin required the standardization of measurement of single-breath DLCO in multicenter clinical trials to optimize test precision...
  72. ncbi Use of doramectin for treatment of sarcoptic mange in five Angora rabbits
    Huseyin Voyvoda
    Department of Internal Medicine, Faculty of Veterinary Medicine, University of Adnan Menderes, PK 17 09016, Aydin Turkey
    Vet Dermatol 16:285-8. 2005
    ..The rabbits first received two subcutaneous injections, 10 days apart, of moxidectin 1% injectable solution at a dosage of 0.2 mg kg(-1) of bodyweight...
  73. ncbi Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
    B I Eriksson
    Orthopedics Department, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    N Engl J Med 345:1298-304. 2001
    ..Surgery for hip fracture carries a high risk of venous thromboembolism, despite the use of current thromboprophylactic treatments. Fondaparinux, a synthetic pentasaccharide, is a new antithrombotic agent that may reduce this risk...
  74. ncbi Maintenance therapy with certolizumab pegol for Crohn's disease
    Stefan Schreiber
    Hospital for General Internal Medicine, Christian Albrechts University, Kiel, Germany
    N Engl J Med 357:239-50. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment with a high binding affinity for tumor necrosis factor alpha that does not induce apoptosis of T cells or monocytes...
  75. ncbi Hand recontouring with calcium hydroxylapatite (Radiesse)
    Kenneth L Edelson
    J Cosmet Dermatol 8:44-51. 2009
    ..The aesthetic result is immediate and generally persists for longer than 6 months. As a treatment option, hand rejuvenation with CaHA (Radiesse) is a very gratifying procedure both to the patient and to the physician...
  76. ncbi Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial
    Richard Shikiar
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Dermatolog Treat 18:25-31. 2007
    ..Psoriasis substantially impairs the health-related quality of life (HRQOL) of patients, and a comprehensive evaluation of treatment includes HRQOL measures...
  77. ncbi Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial
    Eugen Musch
    Department of Internal Medicine, Marienhospital Bottrop, Bottrop, Germany
    Clin Gastroenterol Hepatol 3:581-6. 2005
    ..We performed a randomized, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of recombinant interferon-beta-1a (rIFN-beta-1a) in outpatients with active steroid-refractory ulcerative colitis...
  78. ncbi Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, FL 33136, USA
    Diabetes Care 30:579-85. 2007
    ..The purpose of this study was to evaluate the long-term (2-year) safety and efficacy of inhaled human insulin (Exubera [insulin human (rDNA origin)] inhalation powder) (EXU) in adult patients with type 1 diabetes...
  79. ncbi Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds
    Mary P Lupo
    The Lupo Center for Aesthetic and General Dermatology, Orleans, LA 70124, USA
    Plast Reconstr Surg 121:289-97. 2008
    ..As this generation continues to age, products with greater therapeutic power to correct aging changes will be in growing demand...
  80. ncbi Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis
    K Jeitler
    Diabetes and Metabolism Outpatient Clinic, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Diabetologia 51:941-51. 2008
    ....
  81. ncbi Consensus recommendations on the use of botulinum toxin type a in facial aesthetics
    Jean Carruthers
    Department of Ophthalmology, University of British Columbia, Vancouver, Canada
    Plast Reconstr Surg 114:1S-22S. 2004
    ..Factors unique to each area are presented, and the discussion of each treatment area concludes with a review of key elements that can increase the likelihood of a successful outcome. Summary tables are provided throughout...
  82. ncbi Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly
    Philippe Caron
    Department of Endocrinology, CHU Toulouse, France
    Clin Endocrinol (Oxf) 64:209-14. 2006
    During short-term treatment, monthly subcutaneous injections of lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly...
  83. ncbi Simple technique for lip and nasolabial fold anesthesia for injectable fillers
    Joseph Niamtu
    Oral Maxillofacial and Cosmetic Facial Surgery, 10230 Cherokee Road, Richmond, VA 23235, USA
    Dermatol Surg 31:1330-2. 2005
    ..Minimally invasive cosmetic facial surgery procedures including injectable lip fillers are more popular than ever. Many of the newer fillers are more painful to inject than previous products and require a greater level of pain control...
  84. ncbi Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study
    S Irie
    Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan
    Int J Clin Pharmacol Ther 46:273-9. 2008
    ..c.) liraglutide using doses exceeding those previously studied, and using the stepped titration approach...
  85. ncbi Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy
    A Siebenhofer
    Division of Diabetes and Metabolism, Department of Internal Medicine, Medical University, Leopold Auenbrugger University Hospital, Auenbruggerplatz 15, 8036 Graz, Austria
    Diabetologia 47:1895-905. 2004
    ....
  86. ncbi Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
    C Kapitza
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabet Med 26:1156-64. 2009
    ..The study objectives were to evaluate the pharmacokinetic and pharmacodynamic properties, as well as safety and tolerability, of single doses of taspoglutide, a human glucagon-like peptide-1 (GLP-1) analogue...
  87. ncbi The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study
    Tim Heise
    Profil Institut für Stoffwechselforschung, Hellersbergstr 9, D 41460 Neuss, Germany
    Diabetes Care 28:2161-9. 2005
    ....
  88. pmc Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial
    Susan J Logtenberg
    Diabetes Centre, Isala Clinics, Zwolle, The Netherlands
    Diabetes Care 32:1372-7. 2009
    ..CONCLUSIONS Although we did not observe a significant reduction in hypoglycemic events, improved glycemic control was achieved with the use of CIPII. We saw a 0.8% decrease in A1C and an 11% increase in the time spent in euglycemia...
  89. ncbi Cymetra
    Brian P Maloney
    The Maloney Center for Facial Plastic Surgery, Atlanta, Georgia, USA
    Facial Plast Surg 20:129-34. 2004
    ..The company manufactures a micronized or injectable form called Cymetra. This article reviews the manufacturing, tissue interaction, clinical applications, and anticipated clinical results...
  90. ncbi Leuprorelin acetate granulomas: case reports and review of the literature
    K Yasukawa
    Department of Dermatology, National Hospital Organization Hokkaido Cancer Centre, Sapporo, Hokkaido, Japan
    Br J Dermatol 152:1045-7. 2005
    ..Dermatologists need to know that depot leuprorelin acetate may cause a granulomatous reaction which produces a subcutaneous nodule that might be misdiagnosed as a malignant tumour...
  91. ncbi Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients
    Jonathan T C Kwan
    S W Thames Renal and Transplantation Unit, Epsom and St Helier University Hospitals NHS Trust, St Helier Hospital, Carshalton, Surrey, UK
    Curr Med Res Opin 23:307-11. 2007
    ..To demonstrate safety and efficacy of epoetin delta for the management of anaemia in predialysis patients with chronic kidney disease (CKD)...
  92. ncbi Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes
    Francesca Porcellati
    University of Perugia, Department of Internal Medicine, Section of Internal Medicine, Endocrinology, and Metabolism, Via E dal Pozzo, 06126 Perugia, Italy
    Diabetes Care 30:1261-3. 2007
  93. ncbi Accurate and anatomic midface filler injection by using cheek implants as an injection template
    Joseph Niamtu
    Dermatol Surg 34:93-5; discussion 96. 2008
  94. doi A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults
    Niels H Birkebaek
    Diabetes Care 31:e65. 2008
  95. ncbi An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents
    P L Hofman
    Liggins Institute, University of Auckland, Auckland, New Zealand
    Diabet Med 24:1400-5. 2007
    ....
  96. ncbi Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR
    O Alexopoulou
    Department of Endocrinology, UCL St Luc Hospital, Brussels, Belgium
    Eur J Endocrinol 151:317-24. 2004
    ..The outcome of treatment with this new, long-acting, aqueous formulation of lanreotide was also compared with the patients' previous treatment with octreotide long acting repeatable (LAR)...
  97. ncbi Quality of life of patients undergoing ovarian stimulation with injectable drugs in relation to medical practice in France
    Eric Sedbon
    Reprod Biomed Online 12:298-303. 2006
    ..Clear information is necessary to increase patient's compliance to the treatment. Simplification will make these procedures more patient-friendly and less of a struggle...
  98. ncbi Pharmacokinetics of trefoil peptides and their stability in gastrointestinal contents
    Stine Kjellev
    Immunopharmacology, Novo Nordisk A S, DK 2760 Maaloev, Denmark
    Peptides 28:1197-206. 2007
    ....
  99. ncbi Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats
    Tobias Odenwald
    Department of Pediatrics, University of Heidelberg, Germany
    J Am Soc Nephrol 17:655-62. 2006
    ..R-568 (20 mg/kg per d) or solvent was infused for 4 wk followed by once-daily subcutaneous injections for 2 wk. Total body sodium was measured by neutron activation analysis...
  100. ncbi Diabetes drug update: how 4 new options stack up
    James R Taylor
    University of Florida College of Pharmacy, PO Box 100486, Gainseville, FL 32610 0486, USA
    J Fam Pract 56:207-15. 2007
  101. ncbi The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats
    Shuang Qing Zhang
    School of Pharmaceutical Sciences, Peking University, Beijing 100083, China
    J Pharm Pharmacol 60:99-105. 2008
    ..levels in diabetic rats at all given doses, and restored hyperglycaemic values to normal values after subcutaneous injections at doses of 4 and 8 mg vanadium (V)/kg or after intragastric administration at doses of 14 and 28 mgV/kg, ..

Research Grants63

  1. Gold Nanoparticle Assisted Delivery of Cancer Vaccines and Immune Stimulants
    Adam Lin; Fiscal Year: 2013
    ..in diameter) and tend to stay at injection sites while smaller nanoparticles drain into lymph nodes with subcutaneous injections. They also have known toxicities post degradation...
  2. Epigenetics and choline: mediation of fetal alcohol effects in a rat model
    Carol L Cheatham; Fiscal Year: 2013
    ..If so, subcutaneous injections of choline and vehicle will be necessary...
  3. A Bi-Institutional Pilot Study of Vaccinations for Patients with Low Grade Glioma
    Edward G Shaw; Fiscal Year: 2010
    ..Cancer Institute and the Comprehensive Cancer Center of Wake Forest University of a vaccination regime (subcutaneous injections of glioma-associated antigen [GAA]-derived cytotoxic T-lymphocyte [CTL] epitope-peptides with ..
  4. Orally bioactive exenatie and insulin for type II diabetes
    SAMIR S MITRAGOTRI; Fiscal Year: 2013
    ..in the gastrointestinal tract and poor oral bioavailability, thus requiring administration via subcutaneous injections. The proposed novel oral delivery system for exenatide utilizes multilayered, millimeter-sized ..
  5. Long Circulating Low Molecular Weight Heparins Pulmonary
    Fakhrul Ahsan; Fiscal Year: 2006
    ..of two important disadvantages: [1] like unfractionated heparins, LMWHs still need to be administered by subcutaneous injections and [2] LMWHs have a relatively short duration of action...
  6. Immunomodulatory Mechanisms of Sublingual Immunotherapy
    Louis Rosenthal; Fiscal Year: 2006
    ..sensitization is allergen-specific subcutaneous immunotherapy (SCIT), which involves a series of subcutaneous injections of allergen extracts...
  7. Novel Osteoinductive Protein Synthesizing Implant System
    Kyumin Whang; Fiscal Year: 2003
    ..enhanced the efficacy of the drug to form new bone by approximately two orders of magnitude over local subcutaneous injections. However, no bone was found inside the scaffolds because lovastatin is not chemotactic and bone cells ..
  8. HISTOINCOMPATIBLE MYOBLAST INJECTION AGAINST DYSTROPHY
    Peter Law; Fiscal Year: 1992
    ..Host mice receives subcutaneous injections of CsA daily...
  9. Gene Expression Profiling of the Kveim Siltzbach Test
    Michael Iannuzzi; Fiscal Year: 2005
    ..Four subcutaneous injections will be performed...
  10. MODELS OF THROMBOCYTOPENIA PATHOLOGY & TREATMENT
    Steven McKenzie; Fiscal Year: 2002
    ..We will use daily subcutaneous injections of a TPO peptide mimetic alone or in combination with IVIG or splenectomy...
  11. Interleukin10 Microsphere in Inflammatory Bowel Disease
    NEJAT EGILMEZ; Fiscal Year: 2002
    ..Currently IL-10 is administered to IBD patients systemically either by bolus intravenous or subcutaneous injections. Due to the short in vivo half-life of IL-10, repeated injections of high doses of IL-10 over a period of ..
  12. Melanoma Proteoglycan and Matrix Metalloproteinases
    James McCarthy; Fiscal Year: 2006
    ..in vitro and leads to increased in vitro gelatinolytic activity and accelerated tumor growth following subcutaneous injections into immunocompromised mice...
  13. GENE THERAPY FOR SERUM PROTEIN DEFICIENCIES
    JEFFREY LEIDEN; Fiscal Year: 2000
    ..Many of these diseases are currently treated by repeated intravenous or subcutaneous injections of purified or recombinant proteins...
  14. A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTH
    Robert Lindsay; Fiscal Year: 2009
    ..Currently, the use of 1-34rhPTH is limited to 2 years of daily subcutaneous injections. PTH stimulates bone formation and secondarily bone remodeling, effects which dissipate by about 2 years...
  15. Vector Mediated Vaccine Therapy of Cancer
    Wei Wei Zhang; Fiscal Year: 2004
    ..We will first test for differences in the boosting effect of subcutaneous injections of the ecdhMUC-1/ecdCD40L protein prepared from either bacterial or mammalian cell expression systems...
  16. Metabolic Regulation of Reproduction
    GREGORY FRALEY; Fiscal Year: 2006
    ..Diabetic status will induced pharmacologically with subcutaneous injections of streptozotocin at a dose known to induce diabetes in at least 95% of animals without altering ..
  17. CHANGES IN MOUSE COLON DURING CHEMICAL CARCINOGENESIS
    Thomas Richards; Fiscal Year: 1980
    ..Early changes in the crypt glands will be studied in animals which receive weekly subcutaneous injections of DMH (20 mg/kg body weight) for 1, 2, 4, 8, 12, 16, 20, or 25 weeks and are killed 1, 3, 9, or 25 weeks ..
  18. NASAL ANTHRAX VACCINE DELIVERY FORMULATIONS
    GITA NATARAJAN; Fiscal Year: 2004
    ..The anthrax vaccine now used in the United States requires six subcutaneous injections over an 18-month period, plus yearly boosters...
  19. MECHANISMS OF RAPID RECEPTIVE FIELD REORGANIZATION
    HARRIS SCHWARK; Fiscal Year: 2001
    ..In the second experiment, subcutaneous injections of lidocaine will be made into a neuron's receptive field while monitoring the input resistance of the ..
  20. Contrast Agents for Far Red and Near Infrared Imaging
    Brian Gray; Fiscal Year: 2001
    ..cells were also readily imaged in superficial lung microvessels using intact organ microscopy and at subcutaneous injections sites in nude mice, attesting to the potential for noninvasive, whole body imaging...
  21. Antipsychotic-Like Drug Effects of Neurotensin
    David Feifel; Fiscal Year: 2004
    ....
  22. A Novel Animal Model of Relevance to Schizophrenia
    David Feifel; Fiscal Year: 2009
    ..The successful development of this animal model could significantly enhance the understanding of the underlying causes of schizophrenia-associated abnormalities and improve drug discovery. ..
  23. Improving memory after hippocampal cell loss
    MARK BARDGETT; Fiscal Year: 2007
    ..The results may shed light on new directions in the treatment of memory disorders, and the proposed work will also enhance education in biomedical research among college undergraduates in Kentucky. [unreadable] [unreadable] [unreadable]..
  24. Can beta-lactam antibiotics decrease morphine physical dependence?
    SCOTT RAWLS; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  25. Cannabinoid Regulation of Basal Ganglia Glutamate and GABA
    SCOTT RAWLS; Fiscal Year: 2007
    ..Our outcomes will be a first step in determining whether blocking endocannabinoid inactivation offers any therapeutic advantage over direct activation of cannabinoid receptors with marijuana. [unreadable] [unreadable] [unreadable]..
  26. Mechanistic bases for age-related androgen deficiency
    Johannes Veldhuis; Fiscal Year: 2007
    ..Knowing why testosterone falls should help foster new and safer ways to prevent the problem. [unreadable] [unreadable] [unreadable]..
  27. CRF2 Receptor Modulation of Colonic Response to Stress
    MILLION MULUGETA; Fiscal Year: 2006
    ..abstract_text> ..
  28. MECHANISMS OF CADMIUM TOXICITY IN EPITHELIAL CELLS
    WALTER PROZIALECK; Fiscal Year: 2007
    ..Furthermore, the results of these studies could have more general implications regarding the mechanisms by which toxic substances affect living organisms. ..
  29. Ensemble Disruption of the GnRH-LH-Testosterone Axis
    Johannes Veldhuis; Fiscal Year: 2007
    ..Expected corollary outcomes are enhanced diagnosis, assessment and management of more subtle pathophysiology of the male gonadal axis in puberty and adulthood. ..
  30. Analytical Reconstruction of Feedback Signaling in Aging Men
    Johannes Veldhuis; Fiscal Year: 2008
    ..The present proposal develops a general biomathematical framework for dissecting otherwise observed pathways that control hormone output in aging, stress and disease. [unreadable] [unreadable] [unreadable]..
  31. MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLS
    David Clemmons; Fiscal Year: 2007
    ..The results may suggest novel strategies for interfering with these processes to alter the progression of atherosclerosis. ..
  32. Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
    Shaker Mousa; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  33. Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
    Stephen Davis; Fiscal Year: 2008
    ....
  34. Eliciting Patient Treatment Preferences for Osteoporosis
    Liana Fraenkel; Fiscal Year: 2008
    ..e. daily subcutaneous injections) and costs associated with parathyroid hormone, and iii) estimate how the availability of an extremely ..
  35. Chaperones, ROS systems, & IGF-1:Roles in vascular aging
    David Clemmons; Fiscal Year: 2008
    ..abstract_text> ..
  36. RSA Lecture Series
    Jennifer Thomas; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  37. Novel Active Repressor Model of Human LDL-Receptor Regulation
    Johannes Veldhuis; Fiscal Year: 2008
    ..This would represent a new treatment approach for patients with atherosclerotic disease. [unreadable] [unreadable] [unreadable] [unreadable]..
  38. ENSEMBLE MODEL OF STRESS ACTH-ADRENAL AXIS
    Johannes Veldhuis; Fiscal Year: 2005
    ....
  39. Markers of normoglycemic remission in obese diabetics
    Guillermo Umpierrez; Fiscal Year: 2006
    ..Identifying such markers will facilitate and guide future therapeutic interventions and may identify patients at risk to develop chronic complications of diabetes ..
  40. Prevention of Cancer by Coriolus versicolor Mushroom
    Bela Toth; Fiscal Year: 2004
    ..3: Study the preventative and therapeutic activity of PSK and VPS activity in an Apc transgenic model of intestinal polyp and adenoma formation and its association with immune augmentation. ..
  41. Caveolin-1/lGF-IR Interactions in Oligodendrocytes
    Daniel Mikol; Fiscal Year: 2004
    ..Understanding the interplay between the IGF-IR and caveolin-1 and their control of OLG phenotype will provide insight into the molecular basis of myelination by OLGs and, hopefully, guide new treatments for MS. ..
  42. HOST COMPETENCE FACTORS AFFECT ARBOVIRUS TRANSMISSION
    William Reisen; Fiscal Year: 2003
    ..Studies will assess how alternating sequential infections between vertebrate and vector species that are part of the natural transmission cycle may alter virus genetics and fitness. ..
  43. ARBOVIRUS PERSISTENCE IN SEASONAL WETLANDS
    William Reisen; Fiscal Year: 2002
    ..Virus ecology at wetlands in the Coachella Valley of southeastern California with consistent enzootic activity will be compared with wetlands in the southern San Joaquin Valley where virus activity currently is intermittent. ..
  44. CANCER AND LEUKEMIA GROUP B--MOUNT SINAI
    Lewis Silverman; Fiscal Year: 2002
    ..With these associated investigators in 12 affiliated institutions, Mount Sinai plans to participate in all Group activities. ..
  45. ANDROGEN AS ADJUNCT THERAPY IN RHEUMATOID ARTHRITIS
    John Davis; Fiscal Year: 2002
    ..abstract_text> ..
  46. IGFBP5 AND INTEGRINS AND CONTROLLING IGF1 ACTIONS
    David Clemmons; Fiscal Year: 2002
    ....
  47. Chemokine Potential in Cancer Immunotherapy
    Dean Johnston; Fiscal Year: 2002
    ..Chemokines that prove effective in these models could be directly translated to clinical trials under the direction of Dr. Jean-Claude Bystryn, the CoPI, at NYU Medical Center. ..
  48. IL-lB and Meal Patterns: Ovarian Hormones and CCK
    PETER BUTERA; Fiscal Year: 2002
    ....
  49. TUMOR NECROSIS FACTOR INVOLVEMENT IN FUMONISIN TOXICITY
    RAGHUBIR SHARMA; Fiscal Year: 2001
    ..Results will help in defining the mechanism(s) of fumonisin toxicity, causes of species-specificity, and provide a better appraisal of risk in humans, including modification of fumonisin response by gram-negative infections. ..
  50. THE AGING GH AXIS IN POSTMENOPAUSAL WOMEN
    Johannes Veldhuis; Fiscal Year: 2005
    ..An enhanced knowledge base should aid ultimately in formulating more innovative preventive and interventional strategies to limit hyposomatotropism in older and/or estrogen-deficient humans. ..
  51. ACTIONS OF ESTROGEN IN MATURING GRAAFIAN FOLLICLES
    Johannes Veldhuis; Fiscal Year: 2005
    ..Understanding such fundamental interactions is important to the rational design of alternative strategies to interrupt normal and rescue impaired steroidogenesis in the maturing Graafian follicle and corpus luteum. ..
  52. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes
    David Clemmons; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  53. The effect of nonoxynol-9 on human endometrium
    John Jain; Fiscal Year: 2005
    ..The results of this study will provide important preliminary information on the role of microbicides on endometrial toxicity and may help guide future research priorities. ..
  54. ARTHEROSCLEROSIS IN INSULIN-RESISTANT, HYPERLIPIDEMIC P*
    David Clemmons; Fiscal Year: 2005
    ....
  55. Gene-engineered dendritic cell therapy for diabetics
    Massimo Trucco; Fiscal Year: 2006
    ..The ultimate result could include less intensive or even a complete cessation of insulin replacement therapy in newly-diagnosed diabetics as well as, perhaps, a means of preventing diabetes. ..
  56. STREPTOCOCCAL INACTIVATOR IN HUMAN CHEMOATTRACTANTS
    Paul Cleary; Fiscal Year: 2006
    ..New data indicates that the C5a peptide required for successful colonization and persistence of streptococci in nasal associated lymphoid tissue. ..
  57. Neuroactive Steroid Therapy of Catamenial Epilepsy
    DOODIPALA REDDY; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  58. HUMAN BEHAVIORAL PHARMACOLOGY OF DRUG ABUSE
    George Bigelow; Fiscal Year: 2002
    ..The cocaine dependence clinical trials will evaluate the efficacy of the serotonergic agents tryptophan and fluoxetine in the context of an incentive-based behavior therapy program. ..
  59. Micellar VIP Nanoparticles for Rheumatoid Arthritis
    Israel Rubinstein; Fiscal Year: 2007
    ..abstract_text> ..
  60. Role of the CRF2 Receptor in Ingestive Behavior
    Eric Zorrilla; Fiscal Year: 2005
    ..The proposed studies will address these questions as well to understand better the role of the CRF2 receptor in feeding behavior. ..
  61. EPIDEMIOLOGY OF ANTICOAGULATION IN ATRIAL FIBRILLATION
    Daniel Singer; Fiscal Year: 2005
    ..In all, continued study of our cohort will efficiently provide powerful insights into optimizing stroke prevention strategies for the many older Americans with AF. ..